Bank of New York Mellon’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-146,549
| Closed | -$542K | – | 4473 |
|
|
2017
Q4 | $542K | Buy |
146,549
+333
| +0.2% | +$1.36K | ﹤0.01% | 3588 |
|
|
2017
Q3 | $598K | Sell |
146,216
-8,359
| -5% | -$32K | ﹤0.01% | 3496 |
|
|
2017
Q2 | $574K | Buy |
154,575
+133,962
| +650% | +$532K | ﹤0.01% | 3541 |
|
|
2017
Q1 | $85K | Sell |
20,613
-7,788
| -27% | -$32.7K | ﹤0.01% | 4063 |
|
|
2016
Q4 | $122K | Buy |
28,401
+10,453
| +58% | +$67.6K | ﹤0.01% | 3992 |
|
|
2016
Q3 | $176K | Sell |
17,948
-2,648
| -13% | -$18.8K | ﹤0.01% | 3920 |
|
|
2016
Q2 | $116K | Sell |
20,596
-34,070
| -62% | -$231K | ﹤0.01% | 4025 |
|
|
2016
Q1 | $417K | Buy |
54,666
+400
| +0.7% | +$3.08K | ﹤0.01% | 3519 |
|
|
2015
Q4 | $722K | Sell |
54,266
-1,484
| -3% | -$25.6K | ﹤0.01% | 3357 |
|
|
2015
Q3 | $917K | Sell |
55,750
-12,620
| -18% | -$259K | ﹤0.01% | 3235 |
|
|
2015
Q2 | $1.53M | Buy |
68,370
+12,760
| +23% | +$202K | ﹤0.01% | 3084 |
|
|
2015
Q1 | $544K | Buy |
55,610
+3,108
| +6% | +$30.5K | ﹤0.01% | 3576 |
|
|
2014
Q4 | $598K | Buy |
52,502
+1,018
| +2% | +$11K | ﹤0.01% | 3542 |
|
|
2014
Q3 | $594K | Buy |
51,484
+1,611
| +3% | +$24.6K | ﹤0.01% | 3557 |
|
|
2014
Q2 | $970K | Buy |
49,873
+33,577
| +206% | +$592K | ﹤0.01% | 3329 |
|
|
2014
Q1 | $292K | Buy |
16,296
+2,844
| +21% | +$46.7K | ﹤0.01% | 3751 |
|
|
2013
Q4 | $142K | Hold |
13,452
| – | – | ﹤0.01% | 3937 |
|
|
2013
Q3 | $166K | Hold |
13,452
| – | – | ﹤0.01% | 3837 |
|
|
2013
Q2 | $127K | Buy |
+13,452
| New | +$173K | ﹤0.01% | 3880 |
|
Bank of New York Mellon's CASC Position: Q1 2018 in Review
Bank of New York Mellon sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 146,549 shares — an estimated $542K sold.
Bank of New York Mellon first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $1.53M in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Bank of New York Mellon reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Bank of New York Mellon sold 146,549 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $542K.
- Bank of New York Mellon first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Bank of New York Mellon's Cascadian Therapeutics, Inc. position peaked at $1.53M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Bank of New York Mellon's 13F filing for Q1 2018, filed 15 May 2018.